In the KEYNOTE-012 expansion cohort, response rates were significantly lower in PD-L1-negative patients with recurrent/metastatic HNSCC (4% vs. 22% in PD-L1-positive patients) [6]. This evidence concerns the gene CD274 and head and neck squamous cell carcinoma.